Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Safety concerns and risk management of multiple sclerosis therapies
P. Soelberg Sorensen
*
*
Corresponding author for this work
Department of Clinical Medicine
39
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety concerns and risk management of multiple sclerosis therapies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Risk Management
100%
Relapsing-remitting multiple Sclerosis
100%
Safety Risk
100%
Safety Concerns
100%
Life-threatening
100%
Multiple Sclerosis Treatment
100%
Current Treatment
50%
Initial Treatment
50%
Disease Activity
50%
Alemtuzumab
50%
Daclizumab
50%
Intramuscular Injection
50%
Natalizumab
50%
Glatiramer Acetate
50%
Fingolimod
50%
Patient Selection
50%
Tumefactive multiple Sclerosis
50%
Effective Compounds
50%
Benefit-risk Assessment
50%
Patient Demand
50%
Adverse Effects
50%
Risk-benefit Ratio
50%
Subcutaneous Injection
50%
Treatment Algorithm
50%
Interferon-α (IFN-α)
50%
Severe Adverse Effects
50%
Effective Therapy
50%
Highly Effective
50%
Serious Adverse Effects
50%
Neurologist
50%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Teriflunomide
50%
Fumaric Acid Dimethyl Ester
50%
Subcutaneous Injection
25%
Intramuscular Injection
25%
Glatiramer
25%
Natalizumab
25%
Interferon
25%
Daclizumab
25%
Alemtuzumab
25%
Side Effect
25%
Disease Activity
25%
Risk Evaluation
25%
Fingolimod
25%
Neuroscience
Teriflunomide
66%
Alemtuzumab
33%
Daclizumab
33%